Navamedic ASA Expands Alflorex® distribution to the Netherlands and Denmark

2020-01-24 13:17:00

Navamedic ASA Expands Alflorex® distribution to the Netherlands and Denmark

Oslo, 24 January 2020 – Navamedic ASA (OSE: NAVA), today announces it has entered into an agreement with Alimentary Health for the launch of Alflorex®, a unique product for irritable bowel syndrome (IBS), in the Netherlands in 2H 2020. In December 2019, Navamedic launched Alflorex® in Denmark.

“We are pleased to announce the agreement with Alimentary Health, expanding our distribution of Alflorex® to the Netherlands, a key growth market for Navamedic. About 10-15% of the population have IBS symptoms, and by introducing Alflorex® in more markets we are contributing to improved quality of life by helping IBS sufferers to take back control of their gut health,” says Kathrine Gamborg Andreassen, CEO of Navamedic.

Based on a strategic partnership with PrecisionBiotics Ltd, Navamedic is already distributing Alflorex® to pharmacies in Norway and in December 2019, the company launched the product in pharmacies in Denmark. In addition, Navamedic has the territory rights to launch the product in Iceland.

“Expansion of existing products to new geographies proves the attractiveness of Navamedic’s highly scalable market access platform, and is a recognition of our expertise in introducing, positioning and marketing of products across categories. Both the consumer health gastro therapeutic area and the probiotic market is underdeveloped in our markets, and we aim to drive growth in this market with this unique product,” says Gamborg Andreassen.

Alimentary Health is the owner of Alflorex® and part of the PrecisionBiotics Group, who is developing unique bacteria cultures that have been specifically researched and rigorously tested for specific indications.

Alflorex® for IBS is classified as a medical Class IIb and contains the patented bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is clinically proven to reduce symptoms for IBS, including bloating and gas, abdominal pain, diarrhea and constipation.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
www.oslobors.no